The Role of Adverse Pregnancy Outcomes in Conventional Cardiovascular Risk Prediction
- PMID: 37280462
- DOI: 10.1007/s10995-023-03725-1
The Role of Adverse Pregnancy Outcomes in Conventional Cardiovascular Risk Prediction
Abstract
Objective: Approximately one-third of women in the U.S. experience an adverse pregnancy outcome (APO), which are recognized as sex-specific cardiovascular disease (CVD) risk factors. We examine if APOs confer additional CVD risk beyond that of traditional CVD risk factors.
Methods: Women, age 40-79, with a pregnancy history and no pre-existing CVD were identified in the electronic health record of one health system (n = 2306). APOs included any APO, hypertensive disease of pregnancy (HDP), and gestational diabetes (GDM). Hazard ratios of time to CVD event were estimated from survival models using Cox proportional hazard regression. Discrimination, calibration, and net reclassification of re-estimated CVD risk prediction models including APOs were examined.
Results: There was no significant association between any APO, HDP, or GDM and time to CVD outcome in survival models (95% confidence intervals all include 1). Including any APO, HDP, GDM in the CVD risk prediction model did not significantly improve discrimination and there were no clinically relevant changes in net reclassification of cases and non-cases. The strongest predictor of time to CVD event in the survival models was Black race, with hazard ratios ranging from 1.59 to 1.62, statistically significant for all three models.
Conclusion: Women with APOs did not have an additional risk of CVD, controlling for traditional risk factors in the PCE and this sex-specific factor did not improve risk prediction. Black race was consistently a strong predictor of CVD even with data limitations. Further study of APOs can help determine how to best use this information for CVD prevention in women.
Keywords: Adverse pregnancy outcomes; Cardiovascular disease; Gestational diabetes; Hypertensive disease of pregnancy; Prevention.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.Cochrane Database Syst Rev. 2015 Dec 17;2015(12):CD011507. doi: 10.1002/14651858.CD011507.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Feb 15;2:CD011507. doi: 10.1002/14651858.CD011507.pub3. PMID: 26678256 Free PMC article. Updated.
-
Different intensities of glycaemic control for women with gestational diabetes mellitus.Cochrane Database Syst Rev. 2016 Apr 7;4(4):CD011624. doi: 10.1002/14651858.CD011624.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 Oct 10;10:CD011624. doi: 10.1002/14651858.CD011624.pub3. PMID: 27055233 Free PMC article. Updated.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Screening for gestational diabetes mellitus based on different risk profiles and settings for improving maternal and infant health.Cochrane Database Syst Rev. 2017 Aug 3;8(8):CD007222. doi: 10.1002/14651858.CD007222.pub4. Cochrane Database Syst Rev. 2017. PMID: 28771289 Free PMC article.
-
Preconception sleep, pregnancy loss, and adverse pregnancy outcomes among women with a history of pregnancy loss.Hum Reprod. 2025 Jul 1;40(7):1366-1376. doi: 10.1093/humrep/deaf074. Hum Reprod. 2025. PMID: 40267399 Free PMC article. Clinical Trial.
References
-
- American Diabetes Association. (2014). Standards of medical care in diabetes. Diabetes Care, 37(1), S14–S80. https://doi.org/10.2337/dc14-S014 - DOI
-
- Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Dennison, H. C., Amit, K., Donald, L.-J., William, M. J., Michos, E. D., Miedema, M. D., Daniel, M., Smith, S. C., Virani, S. S., Williams, K. A., Joseph, Y., & Boback, Z. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596–e646. https://doi.org/10.1161/CIR.0000000000000678 - DOI - PubMed - PMC
-
- Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Kemper, A. R., Krist, A. H., Kurth, A. E., Landefeld, C. S., LeFevre, M. L., Mangione, C. M., Phillips, W. R., Owens, D. K., Phipps, M. G., & Pignone, M. P. (2016). Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA, 316(19), 1997–2007. https://doi.org/10.1001/jama.2016.15450 - DOI - PubMed
-
- Carolina Data Warehouse for Health. (2021). Retrieved April 28 2021 from https://tracs.unc.edu/index.php/services/informatics-and-data-science/cdw-h
-
- CDC. (2020). Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_s...
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources